CLINICAL TRIALS PROFILE FOR PEPCID

All Clinical Trials for Pepcid

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00256841 ↗	Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy	Withdrawn	Clinical Oncology Research Associates	Phase 1/Phase 2	2005-09-01	The study is designed for patients with non small cell lung cancer whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer. At this stage of the disease, most patients cannot be cured from the disease, however, treatment can help to live longer and better by keeping the cancer under control. For that purpose, patients traditionally receive radiation therapy or chemotherapy or both treatments in succession. Recently, the administration of both treatment methods given concurrently showed somewhat better results when compared to successive administration. In some studies the drug Taxotere together with radiation performed well in keeping the cancer better under control. Combination of the drug Taxotere together with a compound called 5-FU either as continuous infusion or in its oral form of a pill called "Xeloda" enhanced its anti cancer activity substantially. One goal of this study is to investigate how much of the combination can be given in conjunction with chest radiation. Using X-rays, the study will also evaluate how much shrinkage of the cancer is caused by this treatment directly at the tumor site and other areas where the cancer may have also spread. In this study the radiation will be given on only one day per week in two sessions, rather than divided over five days per week (Monday through Friday) as it is more commonly used. However, both schedules have been found to be equally effective. The treatment program will use increasing doses of the 5-FU medication, either as infusion or as pill to find the highest dose that is tolerated. Once the highest tolerated dose is determined, subsequent patients who will be enrolled will continue to be treated at that dose level. The dose of the drug Taxotere will remain the same throughout. Hypothesis: Our previous research suggests that the combination of Taxotere and 5-FU given together with weekly chest radiation will provide a more convenient form of treatment than the conventional approach and also be at least similar in its efficacy.
NCT00451880 ↗	Study of XL281 in Adults With Solid Tumors	Completed	Exelixis	Phase 1	2007-02-01	The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
NCT00557349 ↗	Ulcer Prevention Study in Post Gastric Bypass Patients	Completed	University of Missouri-Columbia	Phase 4	2006-11-01	This research is to determine which medication, Zegerid (Omeprazole/Sodium Bicarbonate) or Pepcid AC (Famotidine), works best at reducing the chance that a patient will get an ulcer after gastric bypass surgery.
NCT01067066 ↗	A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma	Terminated	Cortice Biosciences, Inc.	Phase 1	2010-02-03	The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolomide, can control metastatic melanoma. The safety of this combination will also be studied. NOTE: Study stopped before progressing to Phase II portion.

Clinical Trial Conditions for Pepcid

Condition Name

Condition Name for Pepcid
Intervention	Trials
Healthy	5
COVID-19	5
Covid19	5
SARS-CoV-2 Acute Respiratory Disease	3

Condition MeSH

Condition MeSH for Pepcid
Intervention	Trials
COVID-19	7
Communicable Diseases	3
Virus Diseases	3
Respiratory Tract Diseases	3

Clinical Trial Locations for Pepcid

Trials by Country

Trials by Country for Pepcid
Location	Trials
United States	42
India	2
Canada	1
Australia	1
Jordan	1

Trials by US State

Trials by US State for Pepcid
Location	Trials
Texas	10
New York	3
Florida	3
Arizona	3
Georgia	2

Clinical Trial Progress for Pepcid

Clinical Trial Phase

Clinical Trial Phase for Pepcid
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Pepcid
Clinical Trial Phase	Trials
Completed	13
Recruiting	8
Not yet recruiting	6

Clinical Trial Sponsors for Pepcid

Sponsor Name

Sponsor Name for Pepcid
Sponsor	Trials
M.D. Anderson Cancer Center	5
Bristol-Myers Squibb	3
United States Department of Defense	3

Sponsor Type

Sponsor Type for Pepcid
Sponsor	Trials
Other	21
Industry	19
U.S. Fed	3

Pepcid (Famotidine): Clinical Trials, Market Analysis, and Projections

Introduction to Pepcid (Famotidine)

Pepcid, commonly known by its generic name famotidine, is a histamine-H2-receptor antagonist used primarily to reduce stomach acid production. It has been on the market since the 1980s and is widely recognized for its safety and efficacy in treating gastrointestinal issues such as heartburn and ulcers.

Clinical Trials for COVID-19 Treatment

During the COVID-19 pandemic, there was significant interest in repurposing existing drugs, including famotidine, to treat the virus.

Early Trials and Anecdotal Evidence

In early 2020, clinical trials were initiated at New York’s Northwell hospitals to investigate whether high doses of intravenous famotidine could alleviate COVID-19 symptoms. The initial interest was sparked by anecdotal evidence suggesting that patients who received famotidine might have better outcomes compared to those who did not[1].

Recent Clinical Trial Findings

More recent trials have provided clearer insights into the efficacy of famotidine in treating COVID-19. A fully-remote, randomized, double-blind, placebo-controlled clinical trial led by The Feinstein Institutes for Medical Research at Northwell Health and Cold Spring Harbor Laboratory found that high doses of famotidine led to earlier resolution of inflammation and alleviated symptoms in patients with COVID-19. This trial, published in the journal Gut in February 2022, showed improvements in symptoms such as breathing, chest congestion, cough, and the return of taste and smell[3][4].

Mechanism of Action

Research suggests that famotidine may activate the vagus nerve, which could help reduce the cytokine storm associated with severe COVID-19. This mechanism is highlighted in a preclinical study published in the journal Molecular Medicine[4].

Market Analysis

Global Antacids Market

The global antacids market, which includes famotidine, is expected to grow at a CAGR of 3.7% from 2025 to 2030. This growth is driven by increasing cases of gastroesophageal reflux disease (GERD) and lifestyle changes leading to gastrointestinal problems, particularly in North America[2].

Key Players

Major players in the antacids market include Sun Pharmaceuticals Ltd, Sanofi S.A, Bayer AG, Johnson & Johnson, and Haleon. These companies play a significant role in the production and distribution of antacids, including famotidine[2].

Regional Market Trends

North America holds the largest share of the global antacids market, while the Asia Pacific region is expected to be the fastest-growing market over the forecast period. The trend towards self-medication in North American countries, such as the United States, is also driving the demand for over-the-counter digestive products like antacids[2].

Market Projections

Growth Drivers

The market for famotidine is anticipated to grow due to several factors:

• Increasing Demand for Digestive Health Products: The rising incidence of GERD and other gastrointestinal issues is driving the demand for antacids.
• Product Approvals: Recent approvals, such as the FDA's approval for Zydus Lifesciences to market famotidine tablets in the United States, are expected to boost the market[2].
• COVID-19 Impact: Although famotidine has not been proven as an effective treatment for COVID-19, the pandemic has highlighted the importance of gastrointestinal medications in managing related symptoms, which could indirectly support market growth[2].

Market Size and Forecast

The global antacids market, including famotidine, is projected to register a significant growth over the forecast period. The market size is expected to increase due to the growing demand for antacids and other digestive health products[2].

Key Takeaways

• Clinical Trials: Recent clinical trials suggest that high doses of famotidine can alleviate COVID-19 symptoms and reduce inflammation, although it is not recommended as a standard treatment without further confirmation.
• Market Growth: The global antacids market, including famotidine, is expected to grow at a CAGR of 3.7% from 2025 to 2030.
• Regional Trends: North America holds the largest market share, while the Asia Pacific region is expected to be the fastest-growing.
• Product Approvals: Recent FDA approvals for famotidine products are likely to boost market growth.

FAQs

What is the current status of famotidine in treating COVID-19?

As of the latest updates, famotidine has shown promise in alleviating COVID-19 symptoms in clinical trials, but it is not yet recommended as a standard treatment without further confirmation[1][3][4].

Which regions are expected to drive the growth of the antacids market?

North America is expected to hold the largest share of the global antacids market, while the Asia Pacific region is anticipated to be the fastest-growing over the forecast period[2].

What are the key drivers for the growth of the famotidine market?

The growth is driven by increasing cases of GERD, lifestyle changes leading to gastrointestinal problems, and recent product approvals such as the FDA's approval for Zydus Lifesciences to market famotidine tablets[2].

Who are the major players in the global antacids market?

Major players include Sun Pharmaceuticals Ltd, Sanofi S.A, Bayer AG, Johnson & Johnson, and Haleon[2].

What is the projected CAGR for the global antacids market from 2025 to 2030?

The global antacids market is expected to register a CAGR of 3.7% from 2025 to 2030[2].

Sources

1. C&EN - American Chemical Society: "Can Pepcid treat COVID-19?" - Updated January 5, 2022.
2. Mordor Intelligence: "Antacids Market Report | Industry Analysis, Size & Forecast Overview".
3. Cold Spring Harbor Laboratory: "Famotidine clinical trial shows COVID-19 symptom reduction" - February 10, 2022.
4. Biospace: "Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows" - May 19, 2022.
5. OpenPR: "Famotidine Market Growth by 2025: QY Research".

Last updated: 2025-01-07